Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Exam Prep1
- Article Type
- Clinical Trial1
- Clinical Study1
- Comparative Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Acta Psychiatr Scand1
Search Results
Sort by
- Book[edited by] Michelle A. Clark, Richard Finkel, Jose A. Rey, Karen Whalen ; series editor Richard A. Harvey.Summary: The Fifth Edition enables rapid review and assimilation of complex information and focuses on the essentials of medical pharmacology. Clear, sequential pictures present mechanisms of action and actually show rather than tell students how drugs work. This book features a signature outline format with more than 500 full-color illustrations and cross-references to other volumes in this bestselling, student-oriented series.
Contents:
Introduction to pharmacology
Drugs affecting the autonomic nervous system
Drugs affecting the central nervous system
Drugs affecting the cardiovascular system
Drugs affecting the endocrine system
Drugs affecting other systems
Chemotherapeutic drugs
Anti-inflammatory drugs and autacoids.Digital Access LWW Health Library (Medical Education) 2012 - ArticleVäisänen E, Naarala M, Kontiainen H, Meriläinen V, Heikkilä L, Malinen L.Acta Psychiatr Scand. 1978 Mar;57(3):193-201.Maprotiline (Ludiomil) and doxepin were compared in the treatment of depression in a double-blind multicentre trial. Four centres and 95 in- and out-patients took part in the trial. The severity of depression was evaluated with the aid of a visual analogue scale and nine target symptoms. Both maprotiline and doxepin diminished neurotic as well as psychotic depression significantly. The mean time of onset of action was 7.0 days in the maprotiline group and 7.7 days in the doxepin group. No statistically significant differences in antidepressive effect were found between the treatments. Two patients in the maprotiline group and four patients in the doxepin group discontinued the treatment because of unwanted effects, one patient in each group because of lack of efficacy and nine patients due to reasons not related to the treatment.